Boston, MANCT06956300Now EnrollingIRB Ready

Prodromal Alzheimer's Disease Clinical Trial in Boston, MA

Access cutting-edge prodromal alzheimer's disease treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Massachusetts General Hospital

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access prodromal alzheimer's disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prodromal alzheimer's disease treatment provided free

Apply for This Boston Location

Check if you qualify for this prodromal alzheimer's disease clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Prodromal Alzheimer's Disease Study in Boston

In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical Alzheimer's disease. This study will use a form of non-invasive brain stimulation called repetitive Transcranial Magnetic Stimulation (rTMS). rTMS will slightly alter activity in an area of your brain that controls cognition. Changes resulting from this stimulation will be measured with behavioral tests, as well as by taking brain images with Magnetic Resonance Imaging (MRI). Participants will come in for one baseline visit followed by 10 days of daily rTMS study visits (Monday through Friday) and an evaluation visit. Then, there will be a 2-week break. After this break, they will return for another baseline visit, an additional 10 days of rTMS, and a final evaluation visit.

Sponsor: Massachusetts General Hospital

Who Can Participate

Inclusion Criteria

Between the ages of 40-99
Native English speakers
Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points
Cognitively normal older adults and individuals with preclinical Alzheimer's disease will be included.

Exclusion Criteria

History of head trauma involving loss of consciousness or alteration in consciousness
Another major neurologic or psychiatric condition
Known presence of a structural brain lesion (e.g. tumor, cortical infarct)
Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.
Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging
History of unprovoked seizures (i.e., seizures that occur in the absence of a clear provocation such as hyponatremia, hypoglycemia, etc.).
Subjects who have a first degree relative (e.g., father, mother or sibling) with a seizure disorder.
Subjects currently taking, or plan to take, medications which are highly epileptogenic. These include: clozapine, high doses of bupropion (i.e., greater than 400mg daily), diphenhydramine, cyclosporine, isoniazid, imipenem, chloroquine, tramadol and theophylline.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06956300) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prodromal Alzheimer's Disease Treatment Options in Boston, MA

If you're searching for prodromal alzheimer's disease treatment options in Boston, MA, this clinical trial (NCT06956300) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prodromal alzheimer's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prodromal alzheimer's disease clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Boston, MA

See all alzheimers disease clinical trials recruiting in Boston — not just this study.

Browse Alzheimers Disease Trials in Boston

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA